NCT02082262View on ClinicalTrials.gov

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Conjunctivitis, Allergic
Interventions
DRUG

AGN-229666

One to two drops of AGN-229666 twice daily in each eye for 10 weeks.

Trial Locations (1)

Unknown

Tokyo

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY